Traws Pharma | 8-K: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.13 12:06
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.34.

EBIT: As of FY2025 Q3, the actual value is USD -4.055 M.

Cash and Cash Equivalents

  • As of September 30, 2025, Traws Pharma, Inc. had cash and cash equivalents of approximately $6.4 million, compared to approximately $21.3 million as of December 31, 2024.

Intangible Assets

  • Intangible assets for the quarter ended September 30, 2025, were $2.6 million, compared to zero for the comparable period in 2024. This increase is due to the acquisition of key intellectual property and other assets associated with a pyrrolidine antiviral compound.

Revenue

  • Revenue for the quarter ended September 30, 2025, was zero, compared to $57 thousand for the comparable period in 2024.

Research and Development (R&D) Expense

  • R&D expenses for the quarter ended September 30, 2025, totaled $2.3 million, a decrease from $5.1 million for the comparable period in 2024. This decrease of $2.8 million primarily relates to reduced expenses in virology and oncology programs.

General and Administrative (G&A) Expense

  • G&A expenses for the quarter ended September 30, 2025, were $1.7 million, compared to $3.5 million for the comparable period in 2024. This decrease of $1.8 million was primarily due to a reduction in professional and consulting fees.

Net Income (Loss)

  • The net loss for the quarter ended September 30, 2025, was $4.0 million, or a net loss of $0.34 per basic and diluted common share, compared to a net loss of $8.5 million, or $1.49 per share, for the quarter ended September 30, 2024.

Outlook / Guidance

  • Traws Pharma anticipates topline data from the Phase 2 studies of ratutrelvir by the end of 2025. The company is also exploring partnership opportunities to support further development of its legacy oncology programs, rigosertib and narazaciclib. Traws Pharma, Inc. anticipates increased demand for COVID therapy as vaccine effectiveness and use decline. The company is focusing on building out the US strategic stockpile for bird flu, with an estimated 300 million to 600 million doses.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.